Patients. Shorter durations of biological anti-tumor necrosis factor-α (TNF) treatment were acceptable in documented cases of TNF-antagonist intolerance. Biologic anti-TNF medications could have been discontinued for any reason (e.g., lack of efficacy, adverse events [AEs]).
contingent upon the success of the primary endpoint analysis. For each endpoint, the test between the combined ustekinumab and placebo groups was performed first. If that test was significant at the 0.05-level, then the pairwise comparison between each dose group and the placebo group was performed. The test for the combined group and ≥1 pairwise comparison needed to be significant to proceed to the next endpoint.
The planned sample size of 300 patients (100 patients per group) was estimated to provide >99% power to detect a significant difference between the placebo and at least one ustekinumab dose group (α=0.05) in the primary endpoint, assuming effect sizes of 20-25% and 25-30%, respectively, among patients not receiving and receiving methotrexate (MTX).
The AE data were summarized as counts and percentages by treatment group and Medical Dictionary for Regulatory Activities (Version 14.1) system-organ class and preferred term, and changes in laboratory parameters were summarized using descriptive statistics. Major cardiovascular AEs (MACE) were predefined to include cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Event rates adjusted for length of follow-up were determined for serious AEs, serious infections, and MACE.
Disposition and baseline characteristics. The first patient provided informed consent on February 26, 2010, and the last patient completed the wk24 and wk60 visits on March 21, 2012 and November 15, 2012, respectively. The trial was conducted at 71 sites in European (168 randomized patients) and North American (144 randomized patients) countries. Seventy-four (23.7%) patients prematurely discontinued study agent through wk60 ( Figure S1 ). had previously received at least one TNF-antagonist, most commonly etanercept, adalimumab, and infliximab. Baseline American College of Rheumatology (ACR) response core set parameters were generally consistent between patients who did and did not receive concomitant MTX, but indicated more active disease in anti-TNF-experienced versus anti-TNF-naïve patients (Table 1) .
Immunogenicity. The incidence of anti-drug antibodies (ADA) against ustekinumab across all treatment groups through wk60 was 9.3% (26 of the 279 patients with evaluable serum samples).
The incidence of ADA through wk60 was lower in patients who received concomitant MTX (6.4%) when compared with those who did not receive concomitant MTX (12.3%). Patients who were positive for ADA tended to have lower clinical efficacy when compared with patients who were negative for ADA. However, the ADA positivity did not preclude a clinical response. There was no apparent association between development of ADA and the development of injection-site reactions.
Physical function and quality of life. Improvements in HAQ-DI scores at wk24 were significantly greater among ustekinumab than placebo-treated patients (p≤0.001; Table S2 ).
Significantly greater proportions of ustekinumab-treated patients achieved a clinically meaningful ≥0.3-unit improvement in HAQ-DI scores versus placebo (p<0.01; Table S2 ), and improvements were generally maintained through wk52 (Table S3 ).
Significant improvements in quality of life were also demonstrated when assessed using SF-36 physical summary and DLQI scores through wk24 (Table S2 ). Improvements were maintained through wk52 (Table S3) .
FACIT-Fatigue scores were significantly improved from baseline to wk24 in ustekinumabtreated patients (all median improvements=3.0) relative to placebo treatment (0.0, all p<0.01).
Similarly, significantly higher proportions of ustekinumab-(all 49.0%) than placebo-(25.8%; all p<0.001) treated patients experienced clinically meaningful improvement (i.e., ≥4 points) in fatigue from baseline to wk24 (Table S2) . Improvements (i.e., ≥4 points) in FACIT-Fatigue score were generally sustained through wk52 (Table S3 ).
Safety.
The most common AEs through wk16 in ustekinumab-treated patients were nasopharyngitis (8.7%), headache (4.8%), and arthralgia (4.3%) ( Table 4 ). The proportions of patients reporting AEs and the types of AEs were generally similar for patients receiving and not receiving MTX at baseline. Similar proportions of ustekinumab-and placebo-treated patients reported AEs among patients who were previously treated with at least one biologic anti-TNF agent and were not appreciably different between these anti-TNF-experienced patients and anti-TNF-naïve patients (data not shown). Nasopharyngitis (13.2%), upper respiratory tract infection (9.1%), headache (7.7%), psoriasis (5.9%), bronchitis (5.6%), and psoriatic arthropathy (5.2%) were the only AEs reported for >5% of ustekinumab-treated patients through wk60 (Table S2 ).
Sixteen patients discontinued study agent due to an AE through wk24, including 5 (2.1%) ustekinumab-treated patients and 11 (10.6%) placebo-treated patients (Table 4) . Excluding patients receiving only placebo before discontinuing treatment, 11 (3.8%) ustekinumab-treated patients discontinued study agent because of an AE through wk60 (Table S2) .
Through wk60, two (1.1%) patients receiving ustekinumab 45 mg and four (3.2%) receiving ustekinumab 90 mg had an injection-site reaction, compared with five (1.6%) patients who received any placebo injection. All injection-site reactions were mild, and none resulted in discontinuation of study agent. Through wk60, no anaphylactic or serum sickness-like reactions associated with study agent were observed. 26/73 (35.6)*** 29/68 (42.6)*** 55/141 (39.0)*** *, **, *** indicate p < 0.05, 0.01, 0.001, respectively, versus placebo. Data are reported as n (%), n/N (%), or median (interquartile range). 1 A "good" or "moderate" EULAR DAS28 response. 2 Among patients with dactylitis at baseline. 3 Among patients with enthesitis at baseline; based on MASES ≥1. 4 Among patients with spondylitis/peripheral joint involvement at baseline. 5 Among patient with ≥ 3% BSA psoriasis involvement at baseline. 6 Among patients with DLQI >1 at baseline. Table S4 . Summary of AEs through week 24 and week 60 among treated patients. 
ACR=American College of Rheumatology, BASDAI=Bath Ankylosing Spondylitis Disease Activity Index, BSA= body surface area, CI=confidence interval, CRP= C-reactive protein, DAS28-CRP=28-joint Disease Activity Score employing CRP, DLQI=Dermatology Life Quality Index, EULAR=European League Against Rheumatism, FACIT-Fatigue=Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI=Health Assessment Questionnaire disability index, MASES=Maastricht Ankylosing Spondylitis Enthesitis Score, MTX=methotrexate, PASI=Psoriasis Area and Severity Index, SF-36=36-item Short-Form health survey, TNF=tumor necrosis factor α, UST=ustekinumab
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